Solifenacin Succinate
Solifenacin, the active substance of Silamil, belongs to a group of anticholinergic medicines. These medicines are used to reduce the activity of an overactive urinary bladder. This allows for less frequent use of the toilet and increases the amount of urine held in the bladder.
Silamil is used to treat symptoms associated with an overactive bladder.
These symptoms include: a sudden, urgent need to urinate without prior pressure on the bladder; frequent urination, incontinence due to the patient not being able to reach the toilet in time.
Before starting to take Silamil, tell your doctor if any of the above disorders are present or have occurred in the past.
Before taking Silamil, discuss with your doctor or pharmacist if:
If any of the above situations apply to the patient now or have applied in the past, inform the doctor before taking Silamil.
Before starting to take Silamil, the doctor will assess whether there are other causes of frequent urination (such as heart failure or kidney disease). If the patient has a urinary tract infection, the doctor will prescribe an antibiotic (a medicine that fights certain bacterial infections).
Tell your doctor or pharmacist about all medicines the patient is taking, has recently taken, or might take.
It is especially important to inform the doctor about the use of such medicines as:
Silamil can be taken with or without food.
Silamil should not be used during pregnancy, unless the doctor recommends it.
Silamil should not be used during breastfeeding, as solifenacin passes into breast milk.
Consult a doctor or pharmacist before taking this medicine.
Silamil may cause blurred vision and sometimes drowsiness or fatigue. Patients who experience such symptoms should not drive or operate machinery.
Silamil contains lactose.The patient should not take this medicine if they have a rare hereditary intolerance to galactose, Lapp lactase deficiency or glucose-galactose malabsorption syndrome.
This medicine should always be taken exactly as prescribed by the doctor. If in doubt, consult the doctor or pharmacist.
Tablets should be swallowed whole with a drink of water. Silamil can be taken with or without food. Do not crush the tablets.
Usually, a dose of 5 mg per day is used, unless the doctor recommends taking a dose of 10 mg per day.
Solifenacin 5 mg tablets in the form of succinate can be used for appropriate dosing.
If the patient takes more Silamil than recommended or if a child accidentally swallows any of these tablets, contact a doctor or pharmacist immediately.
Symptoms of overdose may include: headache, dry mouth, dizziness, drowsiness and vision disturbances, perception of non-existent things (hallucinations), excessive excitement, seizures, breathing difficulties, rapid heartbeat (tachycardia), urine accumulation in the bladder (urinary retention) and pupil dilation.
If the patient forgets to take the medicine at the usual time, they should take a tablet as soon as they remember, unless it is almost time for the next dose. Never take more than one dose per day. If in doubt, consult the doctor or pharmacist.
Do not take a double dose to make up for a missed dose.
Stopping Silamil treatment may cause the return or worsening of symptoms associated with an overactive bladder. The intention to stop treatment should always be discussed with a doctor.
If the patient has any further questions about the use of this medicine, they should ask their doctor or pharmacist.
Like all medicines, Silamil can cause side effects, although not everybody gets them.
Stop taking Silamil and contact a doctor immediately if any of the following symptoms occur:
Frequency not known (frequency cannot be estimated from the available data)
Reporting side effects
If any side effects occur, including those not listed in this leaflet, tell the doctor, pharmacist or nurse. Side effects can be reported directly to the Department of Drug Safety Monitoring of the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products:
Jerozolimskie Avenue 181C, 02-222 Warsaw, tel.: 22 49-21-301, fax: 22 49-21-309,
Website: https://smz.ezdrowie.gov.pl.
Side effects can also be reported to the marketing authorization holder.
By reporting side effects, more information can be gathered on the safety of the medicine.
Keep the medicine out of the sight and reach of children.
Do not use this medicine after the expiry date stated on the carton and blister after the abbreviation "EXP". The expiry date refers to the last day of the month.
The batch number is stated on the packaging after the abbreviation "Lot"
There are no special precautions for storage.
Medicines should not be disposed of via wastewater or household waste. Ask the pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
Silamil 10 mg tablets are light pink, round, coated with "RK76" embossed on one side and smooth on the other. The tablets are approximately 7.5 mm in length.
Silamil is packaged in PVC/PVDC/Aluminum blisters or an HDPE bottle with a capacity of 40 ml.
Sizes of packs containing blisters:
30, 50, 90 or 100 coated tablets
Sizes of packs containing a bottle:
30, 50, 90 or 100 coated tablets
Not all pack sizes may be marketed.
Marketing authorization holder and manufacturer
Ranbaxy (Poland) Sp. z o.o.
Idzikowskiego 16
00-710 Warsaw
S.C. Terapia S.A.
Fabricii Street no. 124
400 632 Cluj Napoca
Romania
Alkaloida Chemical Company Zrt.
Kabay János u. 29
4440 Tiszavasvári
Hungary
Sun Pharmaceutical Industries Europe B.V.
Polarisavenue 87
2132JH Hoofddorp
Netherlands
Netherlands: Solifenacine sun
Germany: SOLIFENACIN BASICS
Spain: Solifenacina sun
United Kingdom (Northern Ireland): Solifenacin succinate
Date of last revision of the leaflet: 02.08.2024
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.